The online edition of the Nikkei Shimbun (dated June 6th) introduced the "AI-programmed medical device for conversational cognitive function testing," jointly developed by Shionogi & Co., Ltd. and FRONTEO.
The device uses KIBIT, a specialized AI developed in-house, to analyze free conversation and screen for cognitive decline, contributing to early detection and treatment.

FRONTEO and Shionogi Pharmaceuticals begin clinical trials of dementia diagnosis support AI
https://www.nikkei.com/article/DGXZQOUC096Z30Z00C25A6000000/

[Reference]

■FRONTEO's AI medical equipment
https://lifescience.fronteo.com/products/dementia/

■Development of conversational AI-programmed medical equipment for cognitive function testing
・FRONTEO and Shionogi & Co., Ltd. enter into a strategic business partnership agreement regarding the dementia and depression diagnostic support AI program business
https://www.fronteo.com/20240214
FRONTEO, Shionogi & Co., Ltd., and Suzuken collaborate to implement a conversational dementia diagnosis support AI program in society
https://www.fronteo.com/20240513
・Designation of AI programmed medical device for conversational cognitive function testing (neuropsychological testing) (SDS-881) as a priority review item for programmed medical devices by the Ministry of Health, Labour and Welfare
https://www.fronteo.com/pr/20250214
・Submitted a clinical trial notification for "Conversational Cognitive Function Testing AI Programmed Medical Device (SDS-881)" jointly developed by FRONTEO and Shionogi Pharmaceuticals
https://www.fronteo.com/pr/20250304
・FRONTEO and Shionogi Pharmaceuticals begin clinical trials for "AI-programmed medical device for conversational cognitive function testing (SDS-881)"
https://www.fronteo.com/pr/20250610